Skip to main content

Select Drug Profiles

FDA Approvals, In the News, Lung Cancer, Oncology

FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

FDA Approvals, In the News

FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

FDA Approvals, In the News

March 08, 2019 - FDA Approvals, News & Updates

Practice Management

Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma

Chase Doyle

Practice Management

Inpatient Costs for Children and Young Adults with Acute Lymphoblastic Leukemia Higher at Specialized Cancer Centers, but for a Good Reason?

Chase Doyle

In the Literature, Oncology

Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with CLL

In the Literature, Oncology

Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer

In the Literature, Oncology

Tisagenlecleucel Leads to High Rates of Durable Response in Relapsed, Refractory DLBCL

Oral Rigosertib plus Azacitidine Combination Shows Promising Results in High-Risk Myelodysplastic Syndromes

Chase Doyle

Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk Myelodysplastic Syndromes

Wayne Kuznar

Page 57 of 244
Results 561 - 570 of 2434